115 related articles for article (PubMed ID: 19402792)
1. Increased CA 19-9 level in patients without malignant disease.
Kim HR; Lee CH; Kim YW; Han SK; Shim YS; Yim JJ
Clin Chem Lab Med; 2009; 47(6):750-4. PubMed ID: 19402792
[TBL] [Abstract][Full Text] [Related]
2. Study of an elevated carbohydrate antigen 19-9 concentration in a large health check-up cohort in China.
Tong Y; Song Z; Zhu W
Clin Chem Lab Med; 2013 Jul; 51(7):1459-66. PubMed ID: 23492572
[TBL] [Abstract][Full Text] [Related]
3. Serum CA 19.9 Levels in Patients With Benign and Malignant Disease: Correlation With the Serum Protein Electrophoretic Pattern.
Gundín-Menéndez S; Santos VM; Parra-Robert M; Pla XF; Fradera JMA; Porto RM
Anticancer Res; 2019 Feb; 39(2):1079-1083. PubMed ID: 30711998
[TBL] [Abstract][Full Text] [Related]
4. CA 19-9 concentration in peripheral and portal blood of patients operated on for pancreatic tumor.
Szwedziak K; Strzelczyk J
Pol Przegl Chir; 2013 Jan; 85(1):20-8. PubMed ID: 23509198
[TBL] [Abstract][Full Text] [Related]
5. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers.
Dai H; Liu J; Liang L; Ban C; Jiang J; Liu Y; Ye Q; Wang C
Respirology; 2014 Jul; 19(5):707-13. PubMed ID: 24903079
[TBL] [Abstract][Full Text] [Related]
6. Serum CA 242: the search for a valid marker of pancreatic cancer.
Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A
Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of serum cancer antigen 19-9 as a tumor screening marker among healthy individuals.
Yang GB
J BUON; 2015; 20(6):1612-6. PubMed ID: 26854460
[TBL] [Abstract][Full Text] [Related]
8. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
Czekierdowski A
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
[TBL] [Abstract][Full Text] [Related]
10. Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer.
Elisei R; Lorusso L; Piaggi P; Torregrossa L; Pellegrini G; Molinaro E; Agate L; Bottici V; Pani F; Cacciato Insilla A; Casella F; Ciampi R; Tognetti I; Materazzi G; Basolo F; Romei C
Eur J Endocrinol; 2015 Sep; 173(3):297-304. PubMed ID: 26034076
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
12. Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases.
Kim S; Park BK; Seo JH; Choi J; Choi JW; Lee CK; Chung JB; Park Y; Kim DW
Sci Rep; 2020 Jun; 10(1):8820. PubMed ID: 32483216
[TBL] [Abstract][Full Text] [Related]
13. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
[TBL] [Abstract][Full Text] [Related]
14. Precystectomy serum levels of carbohydrate antigen 19-9, carbohydrate antigen 125, and carcinoembryonic antigen: prognostic value in invasive urothelial carcinoma of the bladder.
Ahmadi H; Djaladat H; Cai J; Miranda G; Daneshmand S
Urol Oncol; 2014 Jul; 32(5):648-56. PubMed ID: 24680660
[TBL] [Abstract][Full Text] [Related]
15. Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan.
Chang CY; Huang SP; Chiu HM; Lee YC; Chen MF; Lin JT
Hepatogastroenterology; 2006; 53(67):1-4. PubMed ID: 16506366
[TBL] [Abstract][Full Text] [Related]
16. Serum APRIL, a potential tumor marker in pancreatic cancer.
Wang F; Chen L; Ding W; Wang G; Wu Y; Wang J; Luo L; Cong H; Wang Y; Ju S; Shao J; Wang H
Clin Chem Lab Med; 2011 Oct; 49(10):1715-9. PubMed ID: 21612541
[TBL] [Abstract][Full Text] [Related]
17. Effect of percutaneous biliary drainage on serum levels of tumor markers in patients with obstructive jaundice.
Koroglu M; Koroglu BK; Akhan O; Coskun HS; Yildizz H; Yesildag A; Oyar O
Hepatogastroenterology; 2006; 53(70):491-6. PubMed ID: 16995447
[TBL] [Abstract][Full Text] [Related]
18. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.
Van Calster B; Timmerman D; Bourne T; Testa AC; Van Holsbeke C; Domali E; Jurkovic D; Neven P; Van Huffel S; Valentin L
J Natl Cancer Inst; 2007 Nov; 99(22):1706-14. PubMed ID: 18000221
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the bilio-pancreatic region using endoscopic ultrasonography in patients referred with and without abdominal pain and CA 19-9 serum level elevation.
Ulla Rocha JL; Alvarez Sanchez MV; Paz Esquete J; Fernandez Salgado E; Alvarez Alvarez C; Vazquez Sanluis MJ; Ledo Barro L; Vazquez Astray E
JOP; 2007 Mar; 8(2):191-7. PubMed ID: 17356242
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of cancer biomarkers in diabetic and non-diabetic proteinuric patients: a preliminary study.
Turgutalp K; Ozhan O; Helvacı I; Ata A; Arican A; Boztepe B; Kıykım A
Clin Chem Lab Med; 2013 Apr; 51(4):889-95. PubMed ID: 23314541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
